Colombia Organ Transplant Immunosuppressant Drugs Market - Industry Trends and Forecast to 2027

1 INTRODUCTION 11

1.1 OBJECTIVES OF THE STUDY 11

1.2 MARKET DEFINITION 11

1.3 OVERVIEW OF COLOMBIA ORGAN TRANSPLANT MMUNOSUPPRESSANT DRUGS MARKET 11

1.4 LIMITATIONS 13

1.5 MARKETS COVERED 13

2 MARKET SEGMENTATION 14

2.1 MARKETS COVERED 14

2.2 GEOGRAPHICAL SCOPE 15

2.3 YEARS CONSIDERED FOR THE STUDY 15

2.4 CURRENCY AND PRICING 15

2.5 DBMR TRIPOD DATA VALIDATION MODEL 16

2.6 MULTIVARIATE MODELLING 19

2.7 PRODUCTS LIFELINE CURVE 19

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20

2.9 DBMR MARKET POSITION GRID 21

2.10 VENDOR SHARE ANALYSIS 22

2.11 SECONDARY SOURCES 23

2.12 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 26

5 PIPELINE ANALYSIS 27

6 MARKET OVERVIEW 28

6.1 DRIVERS 30

6.1.1 RISING CASES OF ORGAN TRANSPLANTATION 30

6.1.2 GOVERNMENT INITIATIVES TO PROMOTE ORGAN DONATION 30

6.1.3 INCREASING DEMAND OF KIDNEY TRANSPLANTATION 32

6.2 RESTRAINTS 34

6.2.1 STRINGENT REGULATORY PROCEDURES 34

6.2.2 REDUCTION IN MEDICAL TOURISM FOR ORGAN TRANSPLANTS 35

6.2.3 HIGH COST OF IMMUNOSUPPRESSANT DRUGS 36

6.3 OPPORTUNITY 37

6.3.1 DEVELOPING NEW IMMUNOSUPPRESSION FOR THE NEXT GENERATION OF TRANSPLANT RECIPIENTS 37

6.4 CHALLENGES 38

6.4.1 ORGAN REJECTION AND SIDE EFFECTS ASSOCIATED WITH IMMUNOSUPPRESSANT DRUGS 38

6.4.2 LONG WAITLIST FOR RECIPIENTS FOR ORGAN TRANSPLANT 40

7 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE 41

7.1 OVERVIEW 42

7.2 KIDNEY 45

7.3 LIVER 45

7.4 HEART 45

7.5 MLUNG 46

7.6 PANCREAS 46

7.7 OTHERS 46

8 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS 47

8.1 OVERVIEW 48

8.2 CALCINEURIN INHIBITORS 50

8.2.1 TACROLIMUS 51

8.2.2 CYCLOSPORINE 51

8.3 ANTIMETABOLITE IMMUNOSUPPRESSANTS 51

8.3.1 MYCOPHENOLATE MOFETIL 52

8.3.2 MYCOPHENOLATE SODIUM 52

8.3.3 AZATHIOPRINE 52

8.4 STEROIDS 52

8.4.1 PREDNISONE 53

8.4.2 METHYLPREDNISOLONE 53

8.5 M-TOR INHIBITOR 53

8.5.1 EVEROLIMUS 53

8.5.2 SIROLIMUS 54

8.6 MONOCLONAL ANTIBODY 54

8.6.1 BASILIXIMAB 54

8.6.2 MUROMONAB 54

8.7 OTHERS 55

9 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG TYPE 56

9.1 OVERVIEW 57

9.2 GENERICS 59

9.3 BRANDED 60

10 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ROUTE OF ADMINISTRATION 61

10.1 OVERVIEW 62

10.2 ORAL 64

10.3 PARENTERAL 65

11 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY END USER 66

11.1 OVERVIEW 67

11.2 HOSPITALS 69

11.3 TRANSPLANT CENTERS 70

12 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL 71

12.1 OVERVIEW 72

12.2 HOSPITAL PHARMACIES 75

12.3 RETAIL PHARMACIES 75

12.4 ONLINE PHARMACIES 75

13 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, COMPANY LANDSCAPE 76

13.1 COMPANY SHARE ANALYSIS: COLOMBIA 76

14 COMPANY PROFILES 77

14.1 NOVARTIS AG 77

14.1.1 COMPANY SNAPSHOT 77

14.1.2 REVENUE ANALYSIS 77

14.1.3 PRODUCT PORTFOLIO 78

14.1.4 RECENT DEVELOPMENT 78

14.2 PFIZER INC. 79

14.2.1 COMPANY SNAPSHOT 79

14.2.2 REVENUE ANALYSIS 79

14.2.3 PRODUCT PORTFOLIO 80

14.2.4 RECENT DEVELOPMENT 80

14.3 F. HOFFMANN-LA ROCHE LTD 81

14.3.1 COMPANY SNAPSHOT 81

14.3.2 REVENUE ANALYSIS 81

14.3.3 PRODUCT PORTFOLIO 82

14.3.4 RECENT DEVELOPMENT 82

14.4 ASTELLAS PHARMA INC. 83

14.4.1 COMPANY SNAPSHOT 83

14.4.2 REVENUE ANALYSIS 83

14.4.3 PRODUCT PORTFOLIO 84

14.4.4 RECENT DEVELOPMENT 84

14.5 ABBOTT 85

14.5.1 COMPANY SNAPSHOT 85

14.5.2 REVENUE ANALYSIS 85

14.5.3 PRODUCT PORTFOLIO 86

14.5.4 RECENT DEVELOPMENT 86

14.6 ALKEM LABS 87

14.6.1 COMPANY SNAPSHOT 87

14.6.2 REVENUE ANALYSIS 87

14.6.3 PRODUCT PORTFOLIO 88

14.6.4 RECENT DEVELOPMENT 88

14.7 BAYER AG 89

14.7.1 COMPANY SNAPSHOT 89

14.7.2 REVENUE ANALYSIS 89

14.7.3 PRODUCT PORTFOLIO 90

14.7.4 RECENT DEVELOPMENT 90

14.8 BRISTOL-MYERS SQUIBB COMPANY 91

14.8.1 COMPANY SNAPSHOT 91

14.8.2 REVENUE ANALYSIS 91

14.8.3 PRODUCT PORTFOLIO 92

14.8.4 RECENT DEVELOPMENT 92

14.9 DR. REDDY’S LABORATORIES LTD. 93

14.9.1 COMPANY SNAPSHOT 93

14.9.2 REVENUE ANALYSIS 93

14.9.3 PRODUCT PORTFOLIO 94

14.9.4 RECENT DEVELOPMENT 94

14.10 SANOFI 95

14.10.1 COMPANY SNAPSHOT 95

14.10.2 REVENUE ANALYSIS 95

14.10.3 PRODUCT PORTFOLIO 96

14.10.4 RECENT DEVELOPMENT 96

15 QUESTIONNAIRE 97

16 RELATED REPORTS 100

UU

TABLE 1 ORGAN TRANSPLANTS IN COLOMBIA (1966-2017) 30

TABLE 2 TRANSPLANT PROGRAMS PER CITIES AND ORGAN 31

TABLE 3 PRICE OF IMMUNOSUPPRESSANT DRUGS IN USD 36

TABLE 4 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE, 2018-2027 (ORGAN TRANSPLANT) 44

TABLE 5 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE, 2018-2027 (USD MILLION) 44

TABLE 6 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 50

TABLE 7 COLOMBIA CALCINEURIN INHIBITORS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 51

TABLE 8 COLOMBIA ANTIMETABOLITE IMMUNOSUPPRESSANTS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 52

TABLE 9 COLOMBIA STEROIDS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 53

TABLE 10 COLOMBIA M-TOR INHIBITOR IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 53

TABLE 11 COLOMBIA MONOCLONAL ANTIBODY IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 54

TABLE 12 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION) 59

TABLE 13 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 64

TABLE 14 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION) 69

TABLE 15 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 74